Precision BioSciences (NASDAQ:DTIL – Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, August 1st. Analysts expect Precision BioSciences to post earnings of ($0.77) per share for the quarter.
Precision BioSciences (NASDAQ:DTIL – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.10. Precision BioSciences had a negative net margin of 48.10% and a negative return on equity of 131.69%. The business had revenue of $17.58 million during the quarter, compared to analysts’ expectations of $9.35 million. On average, analysts expect Precision BioSciences to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Precision BioSciences Price Performance
Shares of Precision BioSciences stock traded down $0.61 during trading hours on Tuesday, hitting $9.39. The company had a trading volume of 11,728 shares, compared to its average volume of 86,225. The company’s 50-day moving average is $10.84 and its two-hundred day moving average is $11.69. Precision BioSciences has a twelve month low of $8.25 and a twelve month high of $19.43. The company has a market cap of $65.07 million, a P/E ratio of -1.34 and a beta of 1.75.
Analysts Set New Price Targets
Read Our Latest Report on Precision BioSciences
Precision BioSciences Company Profile
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Featured Stories
- Five stocks we like better than Precision BioSciences
- Stock Sentiment Analysis: How it Works
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Most active stocks: Dollar volume vs share volume
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- What Are Dividend Champions? How to Invest in the Champions
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.